ArticleChemMedChem2026
Synthesis and Assessment of the Enantioselectivity in Antitumor Activity of a Library of Novel Chiral Flavone Derivatives.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nature represents a rich source of bioactive compounds, with flavones emerging as privileged scaffolds owing to their multiple biological activities. Their antitumor potential arises from their ability to modulate pathways implicated in cancer progression and multidrug resistance, but structural modifications are often required to improve their pharmacokinetic properties and target selectivity. Incorporating chiral moieties, such as amino acids, may improve their potency and selectivity. Herein, we report the stereoselective synthesis of 32 new chiral derivatives of flavones (CDFs) obtained by coupling four commercial flavones with the enantiomerically pure amino esters and amino acids of tryptophan and tyrosine. Overall, the amino ester derivatives showed greater antiproliferative activity than their parent flavones against four cancer cell lines. 6HF-DTrp (14) and 7HF-DTrp (18) demonstrated micromolar equipotent inhibition with IC50 <21 µM against all cell lines. Most CDFs preferentially affected cancer cells over nontumor HPAEpiC cells, particularly 7HF-DTrp (18), which displayed selectivity indices above 6. Metabolic assays exposed heterogeneous effects on glucose consumption and lactate production, suggesting that CDF-induced cytotoxicity depends on the metabolic flexibility of each tumor phenotype rather than a universal mechanism. Furthermore, in vitro and in silico studies suggest potential P-glycoprotein (P-gp) inhibitory activity for 6HF-DTrp (14) and 7HF-DTrp (18).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.